ABCA1 and atherosclerosis: These findings highlight a pathological shift from protective cholesterol efflux to pro-inflammatory responses in advanced atherosclerosis [52], suggesting stage-specific therapeutic strategies are needed to effectively target ABCA1 dysfunction.